Pain due to diabetic polyneuropathy. MedDRA version: 14.0 Level: LLT Classification code 10012685 Term: Diabetic polyneuropathy System Organ Class: 10029205 - Nervous system disorders
Conditions
Interventions
Product Name: GRT6005 hard capsules (liquid filled with SEDDS_0708)
Product Code: GRT6005
Pharmaceutical Form: Capsule, hard
CAS Number: 863513-91-1
Current Sponsor code: GRT6005, M010239FP, Indolyl-
Sponsors
Grünenthal GmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects must have signed an informed consent form. 2. Male or female subjects aged 18 years to 75 years inclusive at the Enrollment Visit. 3. All subjects must have type 1 or type 2 diabetes mellitus and must have a documented clinical diagnosis of painful DPN with symptoms and signs for at least 3 months and pain present at the Enrollment Visit. 4. The investigator considers the subject’s blood glucose to be controlled by a diet, oral anti-hyperglycemic medication, and/or insulin for at least 3 months prior to enrolling in the trial. This control should be documented. Hemoglobin (HbA1C) should not be greater than 11.0% at the Enrollment Visit. For Germany only: Hemoglobin (HbA1C) should not be greater than 9.5% at the Enrollment Visit. 5. Subjects must be using medically acceptable and highly effective methods of birth control: For women of childbearing potential: A medically acceptable and highly effective method of birth control is defined as any form of contraception with a low failure rate defined as =65 years) yes F.1.3.1 Number of subjects for this age range 200
Exclusion criteria
Exclusion criteria: General: 1. Concurrent participation in another trial, or within 30 days before the Enrollment Visit of this trial. 2. Previous participation in this or other trials with GRT6005 (unless enrollment failure due to technical reason). 3. Previous or current alcohol or drug abuse according to the investigator’s judgment, based on subject’s history, physical examination, or the result of the drug test at the Enrollment Visit or at the Baseline Visit. 4. Previous or current opioid dependency, based on subject’s history, physical examination, or the result of the drug test at the Enrollment Visit or at the Baseline Visit. 5. Female subjects who are breastfeeding. 6. Known or suspected of not being able to comply with the protocol and with the use of the IMP. 7. Any clinically significant disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subject’s safety during trial participation, such as significant pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders (e.g., major depression and psychosis). 8. Employees of the investigator, trial site, or sponsor with direct involvement in the proposed trial or other trials under the direction of that investigator, trial site, or sponsor, as well as family members of employees or the investigator. 9. Subjects with impaired hepatic functionality/cellular integrity determined by bilirubin greater than 2.0 mg/dL and albumin lower than 2.8 g/dL or increased transaminases with alanine aminotransferase or aspartate aminotransferase greater than 3 times the upper limit of normal at the Enrollment or the Prebaseline Visit. 10. History of chronic hepatitis B or C, or human immunodeficiency virus infection, or presence of acute hepatitis A, B, or C within the past 3 months. 11. Subjects with impaired renal function. Creatinine clearance less than 60 mL/min at the Enrollment Visit or the Pre-baseline Visit (calculated from the Cockcroft-Gault formula). 12. Any chronic gastrointestinal disease (e.g., celiac disease or colitis ulcerosa) or previous major abdominal surgery (e.g., Billroth procedure or enteroanastomosis) that might affect drug absorption or excretion. 13. Significant cardiac disease (e.g., unstable angina pectoris, angina pectoris Canadian Cardiovascular Society Class III-IV, acute myocardial infarction within the last 3 months, cardiac insufficiency New York Heart Association Class III-IV). 14. Presence of risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, bradycardia). 15. Marked prolongation of QTc >470 ms at the Enrollment Visit or the Pre-baseline Visit. 16. History of seizure disorder and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy at the Enrollment Visit at the discretion of the investigator. 17. History or presence of malignancy within the past 2 years, with the exception of curative treated subjects or subjects being in remission of cancer for at least 2 years and not requiring treatment. Trial specific: 18. Any scheduled surgery or painful procedure during the course of the trial. 19. Severe or extensive diabetic ulcers or amputations (more than 2 toes) of the limbs or Charcot joints. 20. Clinically relevant history of hypersensitivity, allergy, or contraindications to any of the IMP’s excipients as well as to opioids or paracetamol. 21. Significant vascular disease (e.g., peripheral occlusive arterial diseas
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the analgesic efficacy of fixed doses of 25 µg, 75 µg, and 200 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to diabetic polyneuropathy.;Secondary Objective: -To evaluate the safety and tolerability of fixed doses of 25 µg, 75 µg and 200 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to diabetic polyneuropathy. -To explore the relationship between exposure to GRT6005 and analgesic efficacy and tolerability. -To describe multiple dose kinetics of GRT6005 over 4 weeks in subjects with pain due to DPN. ;Primary end point(s): Change from baseline in the pain intensity scores (on an 11-point NRS) during the last week of the 4-week Treatment Period. The pain intensity scores will be evaluated as the mean of the 2 average pain intensity assessments over the last 12 hours.;Timepoint(s) of evaluation of this end point: Complete last week of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): •Assessment of different responder definitions (rates of 10% to 90% improvement of pain intensity score from baseline) at the treatment visits for Week 1, Week 2, and Week 3, and at the Final Visit. •Change from baseline in the pain intensity scores (on an 11-point NRS) during the entire 4-week Treatment Period. •Change from baseline in the pain intensity scores (on an 11-point NRS) in the first, second, and third week of the 4-week Treatment Period and in the last 24 hours before the Followup Visit. •Weekly mean of current pain intensity (on an 11-point NRS) in the morning and in the evening. Quantitative sensory testing (with a selection of tests, i.e., cotton swab testing, brushevoked pain): changes from Baseline to the treatment visit of Week 1 and to the Final Visit. • NPS: change from baseline to the treatment visit of Week 1 and to the Final Visit. • SF-BPI scores: change from baseline to the Treatment Visit Week 1 and to the Final Visit. • PGIC and CGIC at the treatment visit for Week 1 and at the Final Visit. • LSEQ at the treatment visit for Week 1 and at the Final Visit. • Quality of Life Index – SF-12: Changes from the Baseline Visit to the treatment visit for Week 1 and to the Final Visit. • EQ–5D: Changes from the Baseline Visit (Visit 3) to Visit 7. • Assessment of rescue medication usage during the Treatment Period. Safety and tolerability • Frequency of AEs and percentage of subjects discontinuing the trial due to AEs and drugrelated AEs. • Time to overall withdrawal and time to withdrawal for specific reasons. Endpoints of specific interest • Evaluation of plasma concentration of GRT6005 throughout the Treatment and Follow-up Period. Samples will be taken according to Section 2.2 (schedule of events). • Assessment of potential withdrawal symptoms using COWS at the Follow-up Visit.;Timepoint(s) of evaluation of this end point: Different responder definitions:V4, V5, V6, V7.Change from baseline in pain in | — |
Countries
Germany
Contacts
Public ContactClinical Development Operations
Grünenthal GmbH
Outcome results
None listed